Abstract: Dual bronchodilation with long-acting beta-2 agonists and muscarinic antagonists is recommended in patients with severe to very severe COPD. Among dual bronchodilator combinations, indacaterol/glycopyrronium combination (IGC) received evidence of higher efficacy and good safety compared with monotherapy with either drug as well as with tiotropium. In randomized controlled trials, the primary outcome is usually the change in mean FEV 1 resulting from treatment. However, the functional aspects that influence the physician's choice of the type of management may not be considered important by the patient, based on his perception of the disease. To address such issue, patient-reported outcomes (PROs) were assessed in recent studies. They include patient's perception of breathlessness, physical functioning, global health status, quality of life, use of rescue medications, and patient's report of COPD exacerbations. PRO data from the studies showed a clear improvement in patients' awareness of a better control of the disease in patients treated with IGC. In addition, the latest literature on two important issues influencing patient's preference and adherence, ie, the once-daily administration and the device to be used, confirmed the effectiveness of IGC and the ability of its device (Breezhaler ® ) to result in patient's satisfaction, ease of use, less handling errors, and self-assurance to have inhaled the entire dose.
Introduction
Indacaterol and glycopyrronium belong to the latest generation of beta-2 agonists and muscarinic antagonists, respectively, to be used as bronchodilators in patients with COPD. A large number of trials have demonstrated, as summarized in review articles, the efficacy and safety of indacaterol, [1] [2] [3] [4] glycopyrronium, [5] [6] [7] [8] and the combination of the two drugs. [9] [10] [11] [12] This scientific evidence was highlighted by meta-analyses, resulting in comparable efficacy and safety of both bronchodilators. The first meta-analysis on indacaterol was performed in 2013, including six randomized controlled trials (RCTs) of at least 12 weeks; the parameter used was the OR for likelihood of active treatment at different doses to reduce dyspnea compared with placebo. The ORs were 1.784 (95% CI 1.282-2.482) for the dose of 75 µg, 2.149 (95% CI 1.746-2.645) for the dose of 150 µg, and 2.458 (95% CI 2.010-3.006) for the dose of 300 µg. 13 Later in the same year another meta-analysis included 12 RCTs with a global population of 10,997 patients, with the primary outcome of FEV 1 changes at 12 weeks of treatment. Other bronchodilators, including formoterol, salmeterol, and tiotropium were used as comparators. FEV 1 improved in indacaterol-treated patients compared to placebo 146 Ridolo et al patients by a weighted mean difference (MD) of 0.16 L (95% CI 0.15-0.18 L, P,0.001). Efficacy of indacaterol was similar to formoterol, salmeterol, and tiotropium. 14 In 2015 a Cochrane meta-analysis of 13 RCTs with 9,961 participants was performed, ten trials involving an indacaterol vs placebo comparison, five trials involving an indacaterol vs twice-daily salmeterol, formoterol, and eformoterol comparison. The trial duration was between 12 and 52 weeks. By the Cochrane criteria, an overall strong quality of evidence was found, and the risk of significant bias was minimal in most RCTs. The primary objectives were to compare trough FEV 1 at the end of dosing, exacerbation rates, and quality of life (QoL). Compared with placebo, a significant and clinically relevant improvement in trough FEV 1 was detected with indacaterol, based on a MD of 149.11 mL (95% CI 137.09-161.12). Compared with placebo, a significant improvement in QoL, as measured by the St George Respiratory Questionaire (SGRQ) was found. Compared with twice-daily beta-2 agonists, a small but significant increase in trough FEV 1 was observed with indacaterol (MD 61.71 mL, 95% CI 41. 24-82.17) . Data were insufficient to analyze the differences in exacerbation. The authors concluded that in patients with stable COPD, indacaterol treatment results in significant and clinically meaningful improvements in lung function and QoL compared to placebo. 15 Despite several RCTs evaluated the efficacy of glycopyrronium compared with placebo or other bronchodilators, no meta-analysis exclusively addressing glycopyrronium is available thus far. In a systematic review and network meta-analysis comparing the efficacy of long-acting muscarinic antagonist monotherapies including aclidinium, glycopyrronium, umeclidinium, and tiotropium, which used as primary end point the 12-week trough FEV 1 , the efficacy of glycopyrronium was comparable to tiotropium, which is the established class standard. 16 A meta-analysis on effectiveness and safety of the indacaterol/glycopyrronium combination (IGC) compared with other first-line drugs, particularly tiotropium, is available. Based on the changes in functional indicators and QoL, the authors concluded that IGC was more effective and as safe as tiotropium. 17 The whole evidence on efficacy and safety in COPD patients of indacaterol, glycopyronium, and their combination is a key factor in driving the physician's treatment choice. According to the guidelines on obstructive lung disease (GOLD), either indacaterol or glycopyronium may be prescribed in mild to moderate disease (GOLD level 1-2), while their combination may be prescribed in severe or very severe disease (GOLD level 3-4), inhaled corticosteroids (ICS) being also indicated in the latter. 18 However, the factors influencing physician's decision are not necessarily working in patient's feeling of disease. This makes essential to appreciate the factors influencing the COPD patient preference concerning inhaled bronchodilators.
The role of patient-reported outcomes
As mentioned earlier, the primary end points of RCTs on COPD treatment usually consist of objective measures such as respiratory functional indexes, especially FEV 1 and dyspnea scales. However, to define more precisely the burden of disease as well as the efficacy of a treatment, assessment tools based on patient-reported outcomes (PROs) are needed, the most frequently used being breathlessness, physical functioning, and global health status; the association between PRO data and improved lung function as measured by FEV 1 in 2016 was deemed to be variable, and weak for long-acting β-2 agonist (LABA)/long-acting muscarinic antagonist (LAMA) combinations. 19 However, a recent pooled analysis including 23 RCTs resulted in a different appraisal. In fact, using as PROs dyspnea, as measured by transition dyspnea index (TDI), QoL, as measured by SGRQ, frequency of COPD exacerbations, and use of rescue medication, significant correlations were observed between trough FEV 1 and PROs concerning better SGRQ and TDI scores, less exacerbations, and less rescue medication use. In all end points, active treatments were significantly superior to placebo; in particular, LABA/LAMA treatment achieved better outcomes than either single component. 20 Focusing on IGC, PRO data from five RCTs, one post hoc analysis, one pooled analysis, and one real-life study are available. Table 1 summarizes the main figures from these studies. The first two RCTs were performed in 2013. In the SPARK study, IGC was compared, based on blinded randomization, with glycopirronium alone or with openlabel tiotropium. The PRO used as primary objective was the rate of moderate-to-severe COPD exacerbations, as defined by worsening respiratory symptoms. The results showed the superiority of the dual bronchodilator in respect of glycopyrronium alone in preventing moderate-to-severe exacerbations, as well as in improving health status and lung function. 21 The BEACON study compared in patients with stage II or stage III COPD the efficacy of IGC vs the concurrent administration of indacaterol plus glycopyrronium (IND + GLY) for 4 weeks. Actually, the primary end point was to assess the noninferiority of IGC compared with IND + GLY by the changes in trough FEV 1 
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Management of COPD using indacaterol/glycopyrronium bromide and rescue medication use were also used as PROs. In both treatment groups, a comparable reduction in symptom scores and rescue medication use was found. 22 The following RCT, named BLAZE study, was aimed at comparing the effects of IGC on dyspnea, as measured by a self-administered computerized version of the TDI, vs placebo and tiotropium after 6 weeks of treatment. Further end points were rescue medication use and lung function. A significant difference in TDI total score in favor of IGC compared with placebo (P,0.001) and tiotropium (P=0.021) was detected. Also, a significant improvement in lung function and a significantly lower use of rescue medication were found with IGC compared to the other treatments. 23 In the FLAME study, the effects of co-administration of indacaterol and glycopyrronium were compared with those from the combination of the LABA salmeterol plus the ICS fluticasone (50/500 µg) twice daily during 52 weeks in COPD patients with exacerbations in previous years, using as primary objective the rate of COPD exacerbation. At the final analysis, the rate of exacerbations was 11% lower in the indacaterol-glycopyrronium group than in the salmeterol-fluticasone group (P=0.003), and the time to the first exacerbation was longer for the indacaterolglycopyrronium group than the salmeterol-fluticasone group (71 days vs 51 days, P,0.001); also, the time to the first severe exacerbation was longer for the indacaterolglycopyrronium group (P=0.046). These data drove the authors to conclude that indacaterol-glycopyrronium was more effective than salmeterol-fluticasone in preventing COPD exacerbations. 24 In the FAVOR study were compared the effects of IGC vs tiotropium on peak FEV 1 and also on PROs including patient satisfaction and treatment preference. COPD patients treated with tiotropium prior to enrollment were recruited and randomized to receive once daily either open-label IGC for 4 weeks followed by 4 weeks of tiotropium or vice versa. The primary end point was FEV 1 changes after the treatment period. Patients completing the study had significantly higher FEV 1 after 4 weeks of treatment with IGC vs tiotropium (P=0.0017), and IGC was preferred over tiotropium among both patients and physicians. More patients were very satisfied or satisfied with IGC (79%) compared with tiotropium (58%) concerning dyspnea reduction. The authors highlighted the importance of the improvement of a pivotal PRO such as of patient's dyspnea perception with the open-label IGC compared with tiotropium. 25 A pooled analysis of data from patients with COPD who had participated to six RCTs compared the effects of IGC vs other treatments including salmeterol/fluticasone, glycopyrronium, tiotropium, and placebo. Lung function was measured and health status, dyspnea, other symptoms, and rescue medication use were employed as PROs. Despite significant differences in baseline parameters between men and women, IGC treatment resulted in significantly improved 
148
Ridolo et al lung function vs placebo and all active comparators in men and women. Also, the improvement in dyspnea and health status and the reduction of rescue medication use was higher with IGC compared with all other treatments in both sexes, though the results were generally better in women than in men. 26 A post hoc analysis of the FLAME study evaluated whether IGC reduced the risk of clinically important deterioration compared with salmeterol/fluticasone 50/500 µg twice daily in moderate-to-very severe COPD patients. The judgment of deterioration included a $100 mL decrease in FEV 1 or $4-unit increase in SGRQ total score or a moderateto-severe COPD exacerbation, as assessed by changes from baseline to the end of study after 52 weeks. IGC treatment reduced the incidences of deteriorations and significantly delayed the time to clinically important deterioration (P,0.0001) compared with salmeterol/fluticasone. After 12 weeks, from starting until study ending, patients with clinically important deteriorations had a significantly higher rate of moderate-to-severe exacerbations compared with patients without clinically important deterioration. No significant difference was detected concerning the SGRQ total score in the two treatment groups. 27 Finally, a real-life study in Poland evaluated the impact of routinely administered treatment with either indacaterol, glycopyrronium, or both on PROs from COPD patients, which consisted of health status as assessed by the clinical COPD questionnaire and the level of dyspnea as measured by the modified Medical Research Council (mMRC). The observation period was 26 weeks from the start of treatment. Only procedures of standard, current practice were applied. Improvement in clinical COPD questionnaire and mMRC scores was observed in all treatment groups, but the best results were achieved with the combination of indacaterol and glycopyrronium. 28 Actually, in a recent review on the available PROs in obstructive respiratory diseases, the clinical COPD questionnaire and the COPD assessment test were recommended, based on validity/reliability, responsiveness, practicality, and the short time necessary for completion, for use in both primary care and other clinical settings of daily practice.
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Further issues to assess through patient-reported outcomes
A key issue in patient's preference is the number of daily drug administrations. Therefore, the once-daily use of indacaterol and glycopyrronium in respect to the twice-daily use of other beta-2 agonists and muscarinic antagonists is potentially important. In a cohort study on a large population of 5,869 patients (3,731 with asthma and 2,138 with COPD), around half of the patients preferred the once-daily therapy, one-quarter were unsure, and one-quarter did not prefer the once-daily therapy. No significant correlation between once-daily preference and patients age or gender, disease severity, or frequency of exacerbations was detected when the whole population of patients was analyzed, while in COPD patients the once-daily preference was associated with a high self-perceived need to use controller medications. 30 On the other hand, when short-acting beta-2 agonists (SABA) or short-acting muscarinic antagonists (SAMA) are taken based on pro re nata (PRN) use, patients' preference could be argued. A Cochrane systematic review including eleven studies on patients treated with SABA or SAMA concluded that the strategy to provide a SABA on a PRN basis and then continuing with regular use of either SABA or SAMA would seem cost-effective. 31 However, one must consider that the GOLD guideline admits the PRN use of short-acting bronchodilators only in COPD exacerbations. 18 Also, the device to inhale the drug is critical in influencing patient's appreciation for the prescribed therapy. Several recent studies addressed such aspect. Molimard et al assessed in real life the handling of inhaler device in around 3,000 COPD patients and its relationship with COPD exacerbations. 32 Handling errors were observed in over 50% of inhalations, irrespective of the device used, and critical errors affecting drug delivery were made in 15 . Of interest, the need for hospitalization or emergency room visits for severe COPD exacerbation was 3.3% if no error in the use of device and 6.9% when critical errors were made (P,0.05). These data suggest that training for correct use of inhaler devices should be a basic part of COPD management. 32 In the randomized study by van der Palen et al, errors in the use of inhalers in patients with COPD or asthma who were naïve to the devices were investigated. The devices used were Ellipta ® , Diskus ® , Turbuhaler ® , Handihaler ® , and Breezhaler ® , and also metered-dose inhalers were included. A trained investigator assessed critical errors and demonstrated the correct use of the inhaler to patients who made errors. The results showed that fewer COPD patients made critical errors with Ellipta vs any other device. 33 All the other studies were published in the current year. 
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Management of COPD using indacaterol/glycopyrronium bromide using various inhalers was evaluated by a questionnaire addressing real-world information on correct inhaler use, inhalation technique, device characteristics, training, ease of use, and adherence. The results indicated a significantly lower self-reported adherence in younger patients and patient's preference for in-person demonstration of the device use in respect to video demonstration (89% vs 58%). In 29% of patients, the check for the correct use of the device was not performed, thus resulting in a significantly lower adherence than in patients who were checked (P=0.020). Most patients using Breezhaler ® reported to be confident of having taken a full dose compared with patients using Ellipta 35 The ADVANTAGE study compared in naïve COPD patients the perception of dose delivery confirmation using the Breezhaler ® and Ellipta ® devices and patient's comfort with the inhalers' mouthpiece concerning the easiness in forming a tight seal around the mouthpiece. A new questionnaire on patient perception of inhaler (which was developed and tested in London through cognitive interviews of patients) was used. Patients included in the study filled in the questionnaire after a single inhalation of placebo by inhaler. The results showed that patients were significantly more confident (P,0.0001) of the mechanism of Breezhaler ® than that of the Ellipta ® device and perceived better comfort (P,0.0001) with the Breezhaler ® than the Ellipta ® mouthpiece. 36 A randomized, Phase IV study evaluated the ability of 97 COPD patients to inhale with the least inspiratory effort using three devices (Breezhaler ® , Ellipta, ® and HandiHaler ® ), also assessing the effects on peak inspiratory flow (PIF). For each patient, the inhalation with the highest PIF value was selected for analysis. Both the highest mean PIF value and the lowest mean pressure drop values were detected with Breezhaler ® , followed by Ellipta ® and HandiHaler ® . These results were comparable regardless of the patients' COPD severity, gender, or age. 37 
Conclusion
The effectiveness of the indacaterol/glycopyrronium combination in the treatment of severe COPD is supported by RCTs and meta-analysis. In several studies also PROs were evaluated, including patient's perception of breathlessness, physical functioning, global health status, QoL, use of rescue medications, and patient's report of COPD exacerbations. The PRO data were obtained from RCTs and also in real life, all studies demonstrating a clear improvement in patients' awareness of a better control of the disease. The latest literature added two important issues influencing patient's preference and adherence concerning inhaled drugs: the once-daily administration, which has an advantage over the twice-daily administration, and the device to be used. In most studies performed thus far, a patient's preference for Breezhaler ® , the device used for indacaterol/glycopyrronium combination, was reported, in terms of satisfaction, ease of use, less handling errors, and self-assurance to have inhaled the entire dose. Definitely, the information achieved through PROs, based on the relationship between PRO improvement and better disease control, is essential for the correct management of COPD patients.
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